Timothy Fitzgerald

679 total citations
38 papers, 477 citations indexed

About

Timothy Fitzgerald is a scholar working on Immunology, Economics and Econometrics and Oncology. According to data from OpenAlex, Timothy Fitzgerald has authored 38 papers receiving a total of 477 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Immunology, 10 papers in Economics and Econometrics and 6 papers in Oncology. Recurrent topics in Timothy Fitzgerald's work include Psoriasis: Treatment and Pathogenesis (20 papers), Health Systems, Economic Evaluations, Quality of Life (9 papers) and Migraine and Headache Studies (5 papers). Timothy Fitzgerald is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (20 papers), Health Systems, Economic Evaluations, Quality of Life (9 papers) and Migraine and Headache Studies (5 papers). Timothy Fitzgerald collaborates with scholars based in United States, Canada and Belgium. Timothy Fitzgerald's co-authors include Patricia A. Berglund, Catherine Coulouvrat, Goeran Hajak, Alicia C. Shillington, Judith J. Stephenson, Victoria Shahly, Thomas Roth, Ronald C. Kessler, Jeffrey Vietri and Stephen D. Silberstein and has published in prestigious journals such as SHILAP Revista de lepidopterología, Neurology and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Timothy Fitzgerald

34 papers receiving 469 citations

Peers

Countries citing papers authored by Timothy Fitzgerald

Since Specialization

Citations

This map shows the geographic impact of Timothy Fitzgerald's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Timothy Fitzgerald with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Timothy Fitzgerald more than expected).

Fields of papers citing papers by Timothy Fitzgerald

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Timothy Fitzgerald. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Timothy Fitzgerald. The network helps show where Timothy Fitzgerald may publish in the future.

Co-authorship network of co-authors of Timothy Fitzgerald

This figure shows the co-authorship network connecting the top 25 collaborators of Timothy Fitzgerald. A scholar is included among the top collaborators of Timothy Fitzgerald based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Timothy Fitzgerald. Timothy Fitzgerald is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Patient Disease Characteristics and Treatment Patterns in Mild–Moderate Psoriasis: Results from Real-World Clinical Practice in the United States (PROSPECT Study) 2025 ·Dermatology and Therapy ·(unknown), (unknown), James Lucas, (unknown), Timothy Fitzgerald, (unknown), (unknown)	0
2	Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Interleukin-17A Inhibitors 2024 ·Advances in Therapy ·Philip J. Mease, Shannon Ferrante, Natalie J. Shiff, Timothy Fitzgerald, Soumya D. Chakravarty, Jessica A. Walsh	1
3	54043 Guselkumab for Treatment of Plaque Psoriasis: Persistence and Switching in Real-World Clinical Practices in the US 2024 ·Journal of the American Academy of Dermatology ·Lawrence Rasouliyan, Timothy Fitzgerald, Rachel E. Teneralli, Jing Zhao, David T. Wu	0
4	A Phase II Single Arm Trial of Elective Volume Adjusted De-Escalation Radiotherapy (EVADER) in Patients with Low-risk HPV-related Oropharyngeal Squamous Cell Carcinoma 2024 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), Irene Karam, (unknown), (unknown), (unknown), (unknown), Eric Berthelet, (unknown), Andrea McNiven, Timothy Fitzgerald, Winson Y. Cheung, (unknown), Ur Metser, E. Yu, L. Gauthier, Khalil Sultanem, (unknown), (unknown), (unknown), Wendy R. Parulekar	3
5	Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA 2023 ·Dermatology and Therapy ·Timothy Fitzgerald, Maryia Zhdanava, Dominic Pilon, Aditi Shah, (unknown), Patrick Lefèbvre, Steven R. Feldman	13
6	43312 Long term psoriasis control with guselkumab versus secukinumab and ixekizumab among bio- experienced patients: analysis of drug persistence in large claims database 2023 ·Journal of the American Academy of Dermatology ·Maryia Zhdanava, Timothy Fitzgerald, Dominic Pilon, Rachel E. Teneralli, Aditi Shah, (unknown), Patrick Lefèbvre, Steven R. Feldman	1
7	43038 Long term psoriasis control with guselkumab versus secukinumab and ixekizumab among bio- naïve patients: analysis of drug persistence in large claims database 2023 ·Journal of the American Academy of Dermatology ·Timothy Fitzgerald, Maryia Zhdanava, Dominic Pilon, Rachel E. Teneralli, Aditi Shah, (unknown), Patrick Lefèbvre, Steven R. Feldman	1
8	Preoperative downstaging of pancreatic cancer is associated with improved survival after multi-agent chemotherapy, but not after radiation 2023 ·Surgical Oncology ·(unknown), (unknown), (unknown), David E. Clark, Timothy Fitzgerald	1
9	The Effectiveness of Guselkumab by BMI Category Among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry 2023 ·Advances in Therapy ·April W. Armstrong, Timothy Fitzgerald, Robert R. McLean, Amanda Teeple, Jonathan Uy, Mobolaji Olurinde, (unknown), Lin Guo, Ying Shan, Kristina Callis Duffin	5
10	Real-World Effectiveness of 9–12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry 2022 ·Dermatology and Therapy ·April W. Armstrong, Timothy Fitzgerald, Robert R. McLean, Amanda Teeple, Jonathan Uy, Mobolaji Olurinde, (unknown), Lin Guo, Ying Shan, Kristina Callis Duffin	2
11	Risk of Treatment Discontinuation among Patients with Psoriasis Initiated on Ustekinumab and Other Biologics in the USA 2022 ·Dermatology and Therapy ·Dominic Pilon, Timothy Fitzgerald, Maryia Zhdanava, Amanda Teeple, Laura Morrison, Aditi Shah, Patrick Lefèbvre	4
12	Effectiveness of Guselkumab Therapy among Patients with Plaque Psoriasis with Baseline IGA Score ≥ 2 in the CorEvitas Psoriasis Registry 2022 ·Dermatology and Therapy ·April W. Armstrong, Timothy Fitzgerald, Robert R. McLean, Amanda Teeple, Jonathan Uy, Mobolaji Olurinde, (unknown), Lin Guo, Ying Shan, Kristina Callis Duffin	4
13	Drug Adherence and Persistence of Patients with Moderate to Severe Psoriasis Treated with Biologic Medications in a US Commercially Insured Population 2021 ·Dermatology ·Chang Xu, Amanda Teeple, Bingcao Wu, Timothy Fitzgerald, Steven R. Feldman	6
14	The Impact of Fremanezumab on Headache-Related Disability in Patients with Episodic Migraine using the Migraine Disability Assessment (P4.095) 2018 ·Neurology ·Paul Winner, Timothy Fitzgerald, Sanjay Gandhi, Paul Yeung, Joshua M. Cohen, Yuju Ma, Ernesto Aycardi	1
15	The Positive Impact of Fremanezumab on Work Productivity and Activity Impairment in Patients with Chronic Migraine (S32.007) 2018 ·Neurology ·Richard B. Lipton, Sanjay Gandhi, Timothy Fitzgerald, Paul Yeung, Joshua M. Cohen, Ronghua Yang, Ernesto Aycardi	1
16	Tumor mitotic rate is an independent predictor of survival for nonmetastatic melanoma 2018 ·Surgery ·(unknown), (unknown), Dougald C. MacGillivray, Timothy Fitzgerald	20
17	Residual Effects of Sleep Medications Are Commonly Reported and Associated with Impaired Patient-Reported Outcomes among Insomnia Patients in the United States 2015 ·SHILAP Revista de lepidopterología ·Timothy Fitzgerald, Jeffrey Vietri	34
18	Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trial 2014 ·Experimental Hematology and Oncology ·Teresa Morán, Enriqueta Felip, Vicki L. Keedy, Hossein Borghaei, Frances A. Shepherd, Amelia Insa, Holly Brown, Timothy Fitzgerald, Sriram Sathyanarayanan, John F. Reilly, David Mauro, Karl Hsu, Li Yan, David H. Johnson	27
19	Insomnia, Comorbidity, and Risk of Injury Among Insured Americans: Results from the America Insomnia Survey 2012 ·SLEEP ·Ronald C. Kessler, Patricia A. Berglund, Catherine Coulouvrat, Timothy Fitzgerald, Goeran Hajak, Thomas Roth, Victoria Shahly, Alicia C. Shillington, Judith J. Stephenson, James K. Walsh	73
20	The Associations of Insomnia With Costly Workplace Accidents and Errors 2012 ·Archives of General Psychiatry ·Victoria Shahly, Patricia A. Berglund, Catherine Coulouvrat, Timothy Fitzgerald, Goeran Hajak, Thomas Roth, Alicia C. Shillington, Judith J. Stephenson, James K. Walsh, Ronald C. Kessler	96

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact